Update shared on08 Aug 2025
With both the discount rate and future P/E multiples remaining virtually unchanged, Arteris’ consensus analyst price target also held steady at $14.00.
What's in the News
- Arteris provided updated revenue guidance for Q3 2025 of $16.8–$17.2 million and full year 2025 of $66.0–$70.0 million.
- AMD licensed Arteris' FlexGen NoC IP for next-generation AI chiplets, integrating with AMD’s Infinity Fabric across its AI product portfolio.
- Whalechip licensed Arteris' FlexNoC 5 IP for a custom ASIC supporting advanced near-memory computing architectures aimed at AI applications.
- Arteris was added to several Russell value and small-cap benchmark indexes, enhancing its visibility among investors.
- The company launched Magillem Packaging, new software to automate and simplify chip design and IP packaging for complex SoCs and chiplets.
Valuation Changes
Summary of Valuation Changes for Arteris
- The Consensus Analyst Price Target remained effectively unchanged, at $14.00.
- The Discount Rate for Arteris remained effectively unchanged, moving only marginally from 8.47% to 8.50%.
- The Future P/E for Arteris remained effectively unchanged, moving only marginally from 66.55x to 66.61x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.